UTHR

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.

United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of th.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics' wholly.

While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay after declaring, there is no hard requirement for companies to spend the buyback capacity they authorize.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons made a prodigious investment in the memory company as far back as 2013 – when it was trading at approximately $18 – and saw the equity rise almost exactly 5,000% since.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST, at the Jefferies Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archive.